Biotech Green Day Despite Tech Turmoil: Good Tape Action…Update-2 ABBV

click here Update-2…3/22 ABBV News Kills Momentum of Biotech Stocks  12:30P EDT Abbvie (ABBV) down 13.5 % on disappointing results on blood cancer drug. The big issue is that the drug was recently acquired for $5.8B from Stemcentrx back in 2016. The Company will not seek accelerated approval for Rova-T in Third-Line treatment of patients with relapsed/refractory small […]

Continue Reading 0

Broad Sell-Off Nails Biotech Stocks As Well…Update-1

buy Seroquel visa Update-1… 3/19.   Close is off the lows for Biotech Indices QQQ gap down to $167.10 also at SMA 50 XBI at SMA 50 bottom of channel at $91.89 XLV at $84 approaching February lows of $81 It is very difficult to find news or trends that can help us navigate this sell-off where macro […]

Continue Reading 0

Weak NASDAQ Leaves Biotech Stocks Stalled…Update-1

buy Gabapentin overnight Update-1 …March 18- Market jittery on potential global trade war, rising interest rate concerns and political risk. Also Sales to U.S. retailers fell 0.1% in February a 3 month slide. Biotechs are in a risk-off mode with a weak tape. Dow down 0.47%, NASDAQ down 0.2%, IBB down 0.98%, XBI down 1.56% Biotechs stocks were red across […]

Continue Reading 0

Biotechs Buffeted by Macro News But Should Continue to Outperform…Update-1

Update-1 March 10… Broad Rally Continues Through The Week QQQ Up 4.3% IBB up 4.3% XBI up 4.8% Gene Editing Stocks Surge Biotech stocks soared along with the market as fear about interest rates, tariffs and global politics subsided helped considerably by economic sentiment and jobs. Moreover the employment report showed wage gains revised downward […]

Continue Reading 0

Sluggish Tape And Possibly An End to Celgene Woes?…Update

prednisolone liquid price malaysia Update after close 2/28/18 Tape deteriorates at last hour of trading, a familiar pattern: IBB down 1.83%, QQQ down 0.64%, XBI down 1.88% for day. Biotechs still up YTD with XBI;FBT down 2.35% but still up 8.28% YTD. Celgene, Inc (CELG) sell-off continues down 9% to $87.12 on 27.87M share volume! Hard to find biotech […]

Continue Reading 0

Large Cap Biopharmaceuticals Performance Update 2018: Part 2

Large Cap Biopharmaceuticals: Winners and Losers, Takeaways Here is a brief analysis from data below. Data Sources : Google Finance and FinViz.com. Our Top Picks continue to do well: Abbvie (ABBV), Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD). Laggards in our focus group are Biogen (BIIB) and Celgene (CELG).Both lack drivers and revenue or EPS growth. […]

Continue Reading 0

Rayno BioBeat 2018 #2: Biotech Deal Sparks Rally…Update-1

Update-1 …2/17/18 Good Week for Biotech: FBT up 6.29%, IBB up 4.44%, XBI up 6.26% Biotech stocks continued their strong recovery from the big sell-off in the prior week but about 3% under 2018 highs. Biotech ETFs tracked the QQQ up 5.68% for the week but biotech stocks are leaders YTD beating the S&P 500. […]

Continue Reading 0

Large Cap Biopharma Performance Update 2018-Part 1

Large Cap Biopharmaceuticals Performance Part 1- After Correction Technicals: we are holding the December 2017 bottom but 2018 gains on some indices have been wiped out with peak values on Jan. 26. The FBT was the top performing ETF in 2018 YTD. Many of our picks have outperformed the market. Here are some metrics on […]

Continue Reading 0

How Bad Was The Biotech Selloff Last Week?…Updates-2/6

Updates-2… 2/6/18 Biotechs Down With Overall Market Over 5 Days  Closing Prices as of 2/6/18 XBI up 3% at $91.05 down 5.34% over 5 days IBB up 2% at $109.36 down 7.35% over 5 days QQQ up 2.65% at $162.31 down 5.04% over 5 days By now you have read about all the possible reasons […]

Continue Reading 0

What’s Next After Profit Taking Hits Biotech and Drug Stocks?

Profit Taking Hits Biotech Stocks Disruption Coming to Healthcare? Another Round of Sector Rotation? The biotech sector hit a wall after breaking through to new highs last week. The major news that sparked profit taking on Tuesday was that Amazon, Berkshire Hathaway and J.P.Morgan formed a consortium to address rising healthcare costs by trying to […]

Continue Reading 0